Abiraterone vs Enzalutamide — Which Is Right for You?

Cross-resistance is a genuine concern. Both drugs block the same androgen pathway, so when cancer finds a way around one, it has often found a way around both. ASCO and ESMO guidance acknowledges this, and your oncologist will likely discuss other options — such as chemotherapy or a different targeted agent — alongside any potential switch. The decision depends on why the first drug stopped working and your overall situation, so raise it directly with your team rather than assuming a switch is the next step.

Abiraterone blocks CYP17A1, an enzyme the adrenal glands use to make androgens. The same enzyme is involved in cortisol production, so blocking it disrupts the body's hormone balance and causes a build-up of hormones that raise blood pressure and lower blood potassium. Prednisolone corrects this imbalance. It is not optional — stopping the steroid without telling your team can cause a serious hormonal disturbance. Never stop either medicine without speaking to your oncologist first.

Seizures are uncommon during enzalutamide treatment, but the risk is real because the drug crosses into the brain. It is considerably higher in patients who already have a seizure history, which is why oncologists ask about this before prescribing. If you have had a seizure at any point in your life — including febrile seizures in childhood — tell your team before starting enzalutamide. If you drive, ask your oncologist what applies to you, and check with your state licensing authority if needed.

There is no head-to-head trial clearly showing that one sequence is better than the other. What is established is that cross-resistance between the two drugs is a concern, so oncologists think carefully about sequencing — not just which drug to start, but what comes next if it stops working. The more important question is whether the prescribed drug is appropriate for your specific cancer biology, your other health conditions, and your current disease setting.

For abiraterone: regular blood pressure checks, blood tests for potassium and liver function, and monitoring for fluid retention — particularly in the early months. For enzalutamide: blood pressure and liver function monitoring, and your team will ask about falls, dizziness, or any cognitive changes at each visit. Both drugs also require PSA checks and follow-up imaging to assess whether treatment is working. Your oncologist will set the schedule based on your response and tolerance.

As of the time this page was written, widely available affordable generics of enzalutamide are not established in India the way abiraterone generics are. Generic abiraterone has been available in India for several years and is substantially cheaper than the branded version. If treatment cost is a concern for your family, raise it openly with your oncologist — there may be patient access programmes or government scheme options your team can advise on. It is a reasonable and important question to ask.